These data suggest that a small molecule scFv45-mimetic that can bind and stabilize PTP1B-OX in its inactive state may enhance both insulin and leptin sensitivity, and thus may underlie a viable therapeutic approach to treatment of diabetes and obesity. This evidence concerns the gene PTPN1 and diabetes mellitus.